Patents by Inventor Steve Holmes

Steve Holmes has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES, USES & METHODS
    Publication number: 20240132605
    Abstract: The present invention related to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: August 3, 2023
    Publication date: April 25, 2024
    Inventors: Jamie CAMPBELL, Steve HOLMES, Ian KIRBY, Miha KOSMAC
  • ANTI-OPG ANTIBODIES
    Publication number: 20240026020
    Abstract: The present invention relates to anti-OPG antibodies, and to methods of treatment, uses and pharmaceutical compositions comprising such antibodies, for example in the treatment and prevention of PAH.
    Type: Application
    Filed: May 5, 2023
    Publication date: January 25, 2024
    Inventors: Joana DE ABREU CARVALHO, Steve HOLMES, Allan LAWRIE
  • Antigen binding molecules that bind light
    Patent number: 11827673
    Abstract: The present invention relates antigen binding molecules, particularly antibodies, fragments and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14), competing with LIGHT binding to cellular receptors Herpes virus entry mediator (HVEM) and lymphotoxin beta receptor, and the use of said antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: November 28, 2023
    Assignee: CAPELLA BIOSCIENCE LTD
    Inventor: Steve Holmes
  • Antibodies, uses and methods
    Patent number: 11773175
    Abstract: The present invention related to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: July 30, 2021
    Date of Patent: October 3, 2023
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • Nucleic acids encoding anti-OX40L antibodies
    Patent number: 11753479
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: September 12, 2023
    Assignee: KYMAB LIMITED
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • THERAPEUTIC ANTIBODIES
    Publication number: 20230272097
    Abstract: The invention relates to antibodies which modulate the OX40 signalling pathway to treat inflammatory diseases in companion animals, for example atopic dermatitis (AD) and/or eczema. Related methods and uses are also described.
    Type: Application
    Filed: August 6, 2021
    Publication date: August 31, 2023
    Inventors: Allan BRADLEY, Andrew James THOMPSON, Daniel John BOLLAND, Juexuan WANG, Roberto BANDIERA, Steve HOLMES
  • Anti-OPG antibodies
    Patent number: 11680101
    Abstract: The present invention relates to anti-OPG antibodies, and to methods of treatment, uses and pharmaceutical compositions comprising such antibodies, for example in the treatment and prevention of PAH.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: June 20, 2023
    Assignee: KYMAB LIMITED
    Inventors: Joana De Abreu Carvalho, Steve Holmes, Allan Lawrie
  • Antigen Binding Molecules That Bind LIGHT
    Publication number: 20230035798
    Abstract: The present invention relates to antigen binding molecules, including antibodies, fragments, and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14). The present invention also relates to methods of use of such antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.
    Type: Application
    Filed: April 22, 2022
    Publication date: February 2, 2023
    Inventor: Steve Holmes
  • SYNERGISTIC COMBINATIONS OF OX40L ANTIBODIES FOR THE TREATMENT OF GVHD
    Publication number: 20220372153
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: April 20, 2022
    Publication date: November 24, 2022
    Inventors: Philip Bland-Ward, Miha Kosmac, Steve Holmes, Ian Kirby, Jamie Campbell
  • ANTI-PD-L1 ANTIBODIES
    Publication number: 20220356255
    Abstract: The present invention relates to antigen binding molecules, particularly antibodies, fragments and variants thereof, that bind to the programmed death-ligand 1 (PD-L1) in a pH-dependant manner, competing with PD-L1 binding to the inhibitory receptor programmed death 1 polypeptide (PD-1) and co-stimulatory molecule CD80, and the use of said antigen binding molecules in treating and/or preventing diseases such as cancer.
    Type: Application
    Filed: July 15, 2019
    Publication date: November 10, 2022
    Inventor: Steve HOLMES
  • Methods of treating comprising administering anti-OX40L antibodies
    Patent number: 11396550
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: July 26, 2022
    Assignee: Kymab Limited
    Inventors: Jamie Campbell, Steve Holmes, Ian Kirby, Miha Kosmac
  • ANTI BDCA-2 ANTIBODIES
    Publication number: 20220162322
    Abstract: The present invention relates antigen binding molecules, particularly antibodies, fragments and variants thereof, that bind to BDCA-2 (CLEC4C), and the use of said antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders such as autoimmune diseases.
    Type: Application
    Filed: February 4, 2022
    Publication date: May 26, 2022
    Inventor: Steve HOLMES
  • Antigen binding molecules that bind LIGHT
    Patent number: 11312781
    Abstract: The present invention relates to antigen binding molecules, including antibodies, fragments, and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14). The present invention also relates to methods of use of such antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: April 26, 2022
    Assignee: Capella BioScience Ltd.
    Inventor: Steve Holmes
  • ANTIBODIES, USES & METHODS
    Publication number: 20210395378
    Abstract: The present invention related to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: July 30, 2021
    Publication date: December 23, 2021
    Inventors: Jamie CAMPBELL, Steve HOLMES, Ian KIRBY, Miha KOSMAC
  • Device with integration of light-emitting diode, light sensor, and bio-electrode sensors on a substrate
    Patent number: 11164992
    Abstract: A semiconductor device includes a substrate and a buffer layer disposed on a first portion, a second portion, and a third portion of the substrate. The semiconductor device further includes a multilayer light-emitting diode (LED) stack disposed on the first portion of the substrate, and an optical sensor disposed on the second portion of the substrate. The semiconductor device further includes at least one electrode disposed on the third portion of the substrate, a first conductor in contact with the multilayer LED stack, and a second conductor in contact with the optical sensor. The at least one electrode, the first conductor, and the second conductor are formed of a glassy carbon material.
    Type: Grant
    Filed: November 13, 2019
    Date of Patent: November 2, 2021
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Steve Holmes, Devendra Sadana, Stephen W. Bedell, Bruce Doris, Hariklia Deligianni, Jia Chen
  • ANTIGEN BINDING MOLECULES THAT BIND LIGHT
    Publication number: 20210284747
    Abstract: The present invention relates antigen binding molecules, particularly antibodies, fragments and variants thereof, that bind to the TNF-related cytokine LIGHT (TNFSF14), competing with LIGHT binding to cellular receptors Herpes virus entry mediator (HVEM) and lymphotoxin beta receptor, and the use of said antigen binding molecules in treating and/or preventing inflammatory disorders and immune disorders.
    Type: Application
    Filed: January 24, 2018
    Publication date: September 16, 2021
    Applicant: CAPELLA BIOSCIENCE LTD
    Inventor: Steve HOLMES
  • ANTIBODIES, USES & METHODS
    Publication number: 20210087287
    Abstract: The present invention relates to anti-human OX40L antibodies, new medical uses and methods.
    Type: Application
    Filed: December 8, 2020
    Publication date: March 25, 2021
    Applicant: Kymab Limited
    Inventors: Jamie CAMPBELL, Steve HOLMES, Ian KIRBY, Miha KOSMAC
  • COMPOSITIONS MONOVALENT FOR CD28 BINDING AND METHODS OF USE
    Publication number: 20210047414
    Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
    Type: Application
    Filed: November 2, 2020
    Publication date: February 18, 2021
    Inventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
  • Compositions monovalent for CD28 binding and methods of use
    Patent number: 10919965
    Abstract: Disclosed are domain antibodies that monovalently bind CD28. Domain antibodies that are monovalent for binding of CD28 can inhibit CD28 activity. In one aspect, a domain antibody consists of or comprises a single immunoglobulin variable domain that specifically binds and antagonizes the activity of CD28, in an aspect, without substantially agonizing CD28 activity. In another aspect, the domain antibody is a human domain antibody. The disclosure further encompasses methods of antagonizing CD80 and/or CD86 interactions with CD28 in an individual and methods of treating diseases or disorders involving CD80 and/or CD86 interactions with CD28, the methods involving administering a domain antibody to the individual.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: February 16, 2021
    Assignees: BRISTOL-MYERS SQUIBB COMPANY, DOMANTIS LIMITED
    Inventors: Murray McKinnon, Steven G. Nadler, Suzanne J. Suchard, Brendan Classon, Steve Holmes, Olga Ignatovich, Christopher Plummer, Steve Grant
  • Integrated optogenetic device with light-emitting diodes and glass-like carbon electrodes
    Patent number: 10898725
    Abstract: Embodiments of the invention are directed to an integrated optogenetic device. The integrated optogenetic includes a substrate layer having a first substrate region and a second substrate region. The device further includes a first contact formed over the substrate layer in the first substrate region and a second contact layer formed over the substrate layer in the second region. In addition, the device includes a light-emitting diode (LED) structure communicatively coupled to the first contact layer and a biosensor element communicatively coupled to the second contact layer. The first contact layer is configured to operate as a bottom contact that provides electrical contact to the LED structure. The first contact layer is further configured to be substantially lattice matched with the substrate layer and a bottom layer of the LED structure.
    Type: Grant
    Filed: November 26, 2018
    Date of Patent: January 26, 2021
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Steve Holmes, Stephen W. Bedell, Jia Chen, Hariklia Deligianni, Devendra K. Sadana